Patents Assigned to Adalta Limited
  • Polypeptides which bind C-X-C chemokine receptor type 4 (CXCR4) and methods of treating or reducing the risk of fibrosis and cancer
    Patent number: 11142588
    Abstract: The present disclosure relates to polypeptides (also referred to herein as CXCR4 binding molecules or polypeptides) that are directed against the G-coupled protein receptor CXCR4, also known as Fusin or CD184. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptide; to compositions, and in particular to pharmaceutical compositions that comprise such polypeptides and to uses of such polypeptides for therapeutic or diagnostic purposes.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: October 12, 2021
    Assignee: ADALTA LIMITED
    Inventors: Michael Foley, Andrew Pow, Katherine Griffiths, Samantha Cobb, Katerina Viduka
  • CXCR4 binding molecules and methods of use thereof
    Patent number: 10538596
    Abstract: The present disclosure relates to polypeptides (also referred to herein as CXCR4 binding molecules or polypeptides) that are directed against the G-coupled protein receptor CXCR4, also known as Fusin or CD184. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptide; to compositions, and in particular to pharmaceutical compositions that comprise such polypeptides and to uses of such polypeptides for therapeutic or diagnostic purposes.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: January 21, 2020
    Assignee: Adalta Limited
    Inventors: Michael Foley, Andrew Pow, Katherine Griffiths, Samantha Cobb, Katerina Viduka